Sarepta's Worst Week: A Black Box, 500 Pink Slips, and No Easy Answers
Sarepta added the FDA's most severe safety warning to its Duchenne gene therapy Elevidys after fatal liver failures in pediatric patients, then announced it's cutting 500 workers. The company's flagship drug went from $900M launch year to an uncertain future in record time.
A One-Two Punch No One Wanted
Imagine spending years building the most ambitious gene therapy in rare disease, finally getting it across the finish line, and then watching it all start to unravel in a single week.
That's roughly where Sarepta Therapeutics finds itself right now. The company just added a black box warning (the FDA's most severe safety label) to its flagship Duchenne muscular dystrophy gene therapy, Elevidys. And in the same breath, it announced plans to cut roughly 500 employees, about 36% of its workforce. For a company that was supposed to be biotech's rare disease success story, this is a gut punch.
What Killed the Momentum
The black box warning exists for one reason: kids died.
At least two non-ambulatory pediatric patients (boys who had lost the ability to walk) suffered fatal acute liver failure after receiving Elevidys. One death occurred during a clinical trial called ENVISION. The other happened after the drug was already on the market. In both cases, liver enzymes spiked dramatically, hospitalization came within about two months of infusion, and the outcome was fatal.
That pattern forced the FDA's hand. The agency slapped a boxed warning for serious liver injury and acute liver failure onto the Elevidys label. It also yanked the non-ambulatory indication entirely, meaning the drug can now only be given to patients who can still walk. On top of that, the FDA placed a clinical hold on some of Sarepta's related gene therapy trials for limb-girdle muscular dystrophy and revoked the company's coveted "platform technology" designation for its AAVrh74 viral vector.
Think of it like this: Sarepta didn't just get a speeding ticket. It got its license suspended, its car impounded, and a note on its permanent record.
The Commercial Fallout Is Already Ugly
Elevidys had a monster launch year in 2025, pulling in $898.7 million in net product revenue. That's a blockbuster number for a rare disease gene therapy. But the trajectory was already cracking before this latest news.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Q4 2025 revenue came in at just $110.4 million, well below what analysts expected. William Blair had modeled $128.8 million. Leerink was at roughly $130 million. The stock dropped about 11% on those numbers alone.
Now, with the boxed warning and a smaller approved patient population, Sarepta has set what it calls an Elevidys "annual sales floor" of $500 million for 2026. Management has told investors to model toward the low end of its $1.2 to $1.4 billion total product revenue guidance. Translation: expect things to get worse before they get better.
William Blair analyst Sami Corwin captured the mood when noting that the lack of specific 2026 Elevidys guidance makes it "challenging to determine if the company is seeing a true return in Elevidys demand."
Why 500 People Are Losing Their Jobs
The layoffs aren't a coincidence. They're a survival strategy.
Sarepta is staring down 2027 debt obligations with a drug whose commercial trajectory just got kneecapped. So the company is doing what biotech companies do when the math stops working: cutting deep and fast.
The restructuring targets more than $400 million in annual savings. About $120 million of that comes from the workforce reduction. The rest comes from shelving programs, particularly most of its gene therapy work for limb-girdle muscular dystrophy. The company is pivoting its pipeline focus toward siRNA (small interfering RNA) programs, a different technology altogether.
Sarepta ended 2025 with about $954 million in cash. That sounds like a lot, but gene therapy manufacturing is extraordinarily expensive, and the company needs to keep funding its remaining programs while servicing debt. Suspending financial forecasts entirely (which it did) tells you management doesn't have great visibility into what comes next.
The Bigger Picture for Gene Therapy
Elevidys is currently the only FDA-approved gene therapy for Duchenne muscular dystrophy. That monopoly position should be enormously valuable. Duchenne is a devastating disease that gradually destroys muscle function in boys, usually proving fatal by the late twenties or early thirties. Families are desperate for treatments.
But a black box warning on the only gene therapy option creates a terrible dilemma for doctors and parents. The drug offers a potential one-time treatment that could slow disease progression by roughly 70% over three years, according to Sarepta's latest long-term data. That's meaningful. But "meaningful" looks different when there's a warning about fatal liver failure printed in bold on the label.
Competitors are circling, though none are close. Pfizer had a rival AAV micro-dystrophin therapy (fordadistrogene movaparvovec), but discontinued active clinical development after its Phase 3 trial failed to meet its primary endpoint. Solid Biosciences is working on next-generation vectors. Precision BioSciences has an early-stage gene-editing approach. And Dyne Therapeutics is developing a novel antibody-oligonucleotide conjugate for exon 51 skipping that earned Breakthrough Therapy designation.
None of these will be commercially available anytime soon, which means Elevidys, black box and all, remains the only game in town for gene therapy in Duchenne.
Wall Street Is Split, and That Says Everything
Sarepta's stock is trading around $19 per share with a market cap of roughly $2 billion. The 52-week range stretches from $10.40 to $25.30, so the current price sits squarely in the middle: not a disaster, but not a vote of confidence either.
Analyst sentiment is unusually divided. H.C. Wainwright analyst Mitchell Kapoor has a $5 price target and a Sell rating, arguing that the FDA developments don't signal a path to full approvals and that the stock needs a complete valuation reset. On the other end, some bulls see the high target stretching to $38.
That kind of spread (a $5-to-$38 range on a $19 stock) tells you that nobody really knows what Sarepta is worth right now. The answer depends almost entirely on whether Elevidys can rebuild physician confidence and sustain commercial demand with a smaller, ambulatory-only patient population.
The Road Ahead Is a Tightrope
Sarepta's management is calling 2026 a "reset year." That's corporate-speak for "things are bad and we need time." The company plans to ramp up its commercial outreach in the second half of 2026, hoping to rebuild demand with better education around the drug's safety monitoring protocols.
But rebuilding trust after patient deaths is one of the hardest things a company can do, especially in pediatrics. Parents researching Elevidys will find the black box warning. Doctors will have the conversation about fatal liver failure. Insurance companies will scrutinize every authorization.
Sarepta built something remarkable with Elevidys: a one-time gene therapy that could change the course of a fatal childhood disease. The science is still there. The need is still desperate. But the path from here requires navigating safety concerns, financial constraints, and a workforce that just lost a third of its colleagues, all at the same time.
That's not a reset. That's a reinvention.
Funding & Financings
5 min read
The Gene Editing Company That Wants to Replace Your Cholesterol Meds
A gene editing startup co-founded by a Nobel laureate just filed to go public, and it's not chasing rare diseases. Scribe Therapeutics wants to use CRISPR to replace your daily cholesterol pills with a single dose that silences the genes behind heart disease.
